Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
The data, while limited, indicate that the firm's blood-only assay may be able to match the performance of existing commercial tissue-informed competitors.
NuProbe, AcornMed to Develop Cancer Minimal Residual Disease Detection Products
The companies aim to validate NuProbe's blocker displacement amplification technology for MRD monitoring in genitourinary and hematologic cancer patients.
Guardant Health Receives New York State Approval for Guardant Reveal MRD Test
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
Liquid Biopsy MRD Detection Eyed as Decision Tool for Oligometastatic Colorectal Cancer Patients
Premium
If the team is successful in expanding on the results that they reported last month, it could open a new application for the still nascent circulating tumor DNA technology.
Broad Team to Improve Minimal Residual Disease Detection With Mutation Enrichment Sequencing Method
Premium
The team plans to integrate the method, which combines mutation enrichment with duplex sequencing, into its platform to detect minimal residual disease in blood.